Identification of new RAD51D-regulating microRNAs that also emerge as potent inhibitors of the Fanconi anemia/homologous recombination pathways.
Journal
Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958
Informations de publication
Date de publication:
16 12 2022
16 12 2022
Historique:
received:
28
03
2022
revised:
28
06
2022
accepted:
27
07
2022
pubmed:
30
7
2022
medline:
21
12
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
The Fanconi anemia (FA) and homologous recombination (HR) pathways, which partially overlap and include RAD51 and its paralogs, are key for the repair of different types of DNA damage, such as DNA interstrand crosslinks. First, to broadly assess the impact of microRNA-mediated regulation, we examined microRNA expression profiles in five isogenic fibroblast cell pairs, either deficient in DNA repair due to germline mutations in FANCA, FANCB, FANCC, FANCI or BRIP1/FANCJ or proficient due to correction with retroviral vectors. In each pair, we observed lower abundance of specific microRNAs in the FA-deficient cells. From the list of microRNAs, we experimentally confirmed the effects of miR-141-3p and miR-369-3p targeting RAD51B and miR-15a-5p, miR-494-3p as well as miR-544a targeting RAD51D. However, by western blotting, only RAD51D protein was reduced by a mixture of its regulating microRNAs. Gene ontology analyses and identification of additional FA/HR factors as targets of miR-15a-5p, miR-494-3p and miR-544a strongly suggested the widespread influence of these microRNAs on HR. Interestingly, only miR-494-3p directly reduced RAD51 foci formation, while a mixture of miR-15a-5p, miR-494-3p and miR-544a strongly reduced HR activity in green fluorescent protein (GFP) repair assays. In summary, by successfully employing this novel loss- and gain-of-function strategy, we have identified new microRNAs strongly inhibiting HR in mammalian cells. Understanding and modulating such miRNA regulation of DNA repair genes/pathways might help to overcome the reduced repair capacity of FA patients with biallelic hypomorphic mutations or help to engineer synthetic lethality strategies for patients with mutations in cancer-associated FA/HR genes.
Identifiants
pubmed: 35904444
pii: 6651752
doi: 10.1093/hmg/ddac177
pmc: PMC9759333
doi:
Substances chimiques
DNA-Binding Proteins
0
MicroRNAs
0
RAD51D protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4241-4254Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM134731
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
EMBO Mol Med. 2011 May;3(5):279-90
pubmed: 21472990
Nucleic Acids Res. 2008 Jan;36(Database issue):D149-53
pubmed: 18158296
Cancer Res. 2012 Aug 15;72(16):4037-46
pubmed: 22761336
Eur J Hum Genet. 2017 Dec;25(12):1345-1353
pubmed: 29255180
Blood. 2011 Feb 17;117(7):2247-56
pubmed: 20971953
Nat Genet. 2005 May;37(5):495-500
pubmed: 15806104
BMC Cancer. 2013 Oct 19;13:484
pubmed: 24139550
Mol Oncol. 2020 Jan;14(1):180-196
pubmed: 31637848
Nature. 2005 Feb 17;433(7027):769-73
pubmed: 15685193
Genome Biol. 2004;5(3):R13
pubmed: 15003116
Methods Mol Biol. 2012;920:379-91
pubmed: 22941618
Hum Mol Genet. 2015 Sep 15;24(18):5093-108
pubmed: 26085575
EMBO J. 2002 Sep 2;21(17):4663-70
pubmed: 12198168
Chin J Cancer. 2015 Sep 14;34(11):485-7
pubmed: 26369335
J Med Genet. 2012 Oct;49(10):618-20
pubmed: 23054243
Annu Rev Genet. 2011;45:247-71
pubmed: 21910633
Nat Genet. 2010 May;42(5):406-9
pubmed: 20400963
Curr Biol. 2002 Apr 30;12(9):735-9
pubmed: 12007417
Biochimie. 2019 Dec;167:42-48
pubmed: 31509760
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Genes (Basel). 2018 Dec 13;9(12):
pubmed: 30551670
Cold Spring Harb Perspect Biol. 2014 Sep 02;6(9):a023192
pubmed: 25183833
Cell. 2009 May 29;137(5):807-10
pubmed: 19490890
Stem Cells Dev. 2011 Aug;20(8):1383-94
pubmed: 21067317
Nat Methods. 2015 Aug;12(8):697
pubmed: 26226356
Genes Dev. 1999 Oct 15;13(20):2633-8
pubmed: 10541549
NPJ Breast Cancer. 2021 Nov 15;7(1):143
pubmed: 34782604
Sci Rep. 2019 Feb 28;9(1):3008
pubmed: 30816202
Oncotarget. 2017 Jan 31;8(5):7231-7247
pubmed: 27980227
Annu Rev Genet. 2020 Nov 23;54:25-46
pubmed: 32663049
Nat Struct Mol Biol. 2007 Jun;14(6):564-7
pubmed: 17460694
Cancer Metastasis Rev. 2009 Dec;28(3-4):369-78
pubmed: 20012925
Elife. 2014 Apr 30;3:e02445
pubmed: 24843000
Annu Rev Biochem. 2021 Jun 20;90:107-135
pubmed: 33882259
Cell. 2018 Mar 22;173(1):20-51
pubmed: 29570994
Nucleic Acids Res. 2005 Nov 27;33(20):e179
pubmed: 16314309
Biochem Biophys Res Commun. 2015 Oct 16;466(2):180-5
pubmed: 26343459
Cell Death Dis. 2018 Apr 18;9(5):447
pubmed: 29670086
Nat Genet. 2007 Feb;39(2):162-4
pubmed: 17200671
Nat Genet. 2010 May;42(5):410-4
pubmed: 20400964
Nat Genet. 2005 Sep;37(9):931-3
pubmed: 16116424
Blood. 2003 Feb 15;101(4):1249-56
pubmed: 12393516
N Engl J Med. 2010 May 20;362(20):1909-19
pubmed: 20484397
PLoS One. 2011 Jan 20;6(1):e16138
pubmed: 21283765
Toxicol Sci. 2011 Oct;123(2):480-90
pubmed: 21750350
Cell Death Dis. 2018 May 24;9(6):632
pubmed: 29795397
Cytogenet Genome Res. 2002;98(2-3):126-35
pubmed: 12697994
J Cell Physiol. 2010 May;223(2):289-98
pubmed: 20112282
BMC Genomics. 2013 Feb 19;14:111
pubmed: 23418963
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
Anticancer Res. 2018 Mar;38(3):1317-1325
pubmed: 29491055
Sci Rep. 2021 Feb 24;11(1):4420
pubmed: 33627769
Nat Commun. 2015 Dec 18;6:8829
pubmed: 26681308
Mol Cancer Res. 2013 Dec;11(12):1564-73
pubmed: 24088786
PLoS One. 2020 Jan 10;15(1):e0221681
pubmed: 31923208
Nucleic Acids Res. 2016 Aug 19;44(14):6803-16
pubmed: 27179029
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4536-41
pubmed: 24616504
Oncotarget. 2019 Jul 08;10(43):4407-4423
pubmed: 31320994
Oncotarget. 2017 Nov 3;9(1):1279-1290
pubmed: 29416694
Mol Ther Nucleic Acids. 2015 Dec 15;4:e270
pubmed: 26670277
Nat Genet. 2011 Aug 07;43(9):879-882
pubmed: 21822267
Mutat Res. 2009 Jul 31;668(1-2):4-10
pubmed: 19622403
Nat Rev Cancer. 2011 Jun 24;11(7):467-80
pubmed: 21701511
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
RNA. 2004 Dec;10(12):1957-66
pubmed: 15525708
Nat Rev Mol Cell Biol. 2020 May;21(5):284-299
pubmed: 32094664
Annu Rev Cancer Biol. 2019 Mar;3:457-478
pubmed: 30882047
Arch Biochem Biophys. 2019 May 15;666:73-82
pubmed: 30951682
Sci Rep. 2020 Feb 24;10(1):3284
pubmed: 32094412
Eur Rev Med Pharmacol Sci. 2017 Nov;21(21):4810-4818
pubmed: 29164582
Mol Cell. 2010 Nov 24;40(4):619-31
pubmed: 21055983
J Clin Invest. 2013 Sep;123(9):3839-47
pubmed: 23934222
Nucleic Acids Res. 2009 Apr;37(6):1740-54
pubmed: 19129235
J Med Genet. 2016 Oct;53(10):672-680
pubmed: 27208205
Cell. 2006 Sep 22;126(6):1203-17
pubmed: 16990141
Stem Cells Dev. 2016 Aug 1;25(15):1119-33
pubmed: 27308945
Toxicology. 2016 Feb 17;344-346:1-6
pubmed: 26860703
Carcinogenesis. 2015 Nov;36(11):1363-71
pubmed: 26264654
Molecules. 2018 Oct 27;23(11):
pubmed: 30373256
Mol Med Rep. 2019 Jan;19(1):581-588
pubmed: 30431102
Oncol Lett. 2017 Jul;14(1):1054-1060
pubmed: 28693273
Genome Biol. 2019 Jan 22;20(1):18
pubmed: 30670076
Elife. 2015 Aug 12;4:
pubmed: 26267216